Who Owns Taysha Gene Therapies Stock?
NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 2:14 PM ET
Ownership breakdown
- Held by institutions
- 94.06%
- Institutions (% of float)
- 103.88%
- Held by insiders
- 9.45%
- Institutional holders
- 274
- Institutions 90.6%
- Insiders 9.4%
- Public and other 0.0%
Who owns Taysha Gene Therapies stock?
Institutional investors own about 94.1% of Taysha Gene Therapies's shares, spread across 274 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 9.45% of TSHA.
The largest institutional holders are Avoro Capital Advisors LLC (7.33%), RA Capital Management, L.P. (7.23%) and Goldman Sachs Group Inc (6.97%). Together, the top 10 institutions control 54.5% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their TSHA positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of TSHA
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Avoro Capital Advisors LLC | 23.89M | 7.33% | +10.1% |
| RA Capital Management, L.P. | 23.56M | 7.23% | 0.0% |
| Goldman Sachs Group Inc | 22.71M | 6.97% | +1.5% |
| Blackrock Inc. | 20.69M | 6.35% | +12.7% |
| Vestal Point Capital, LP | 19.41M | 5.96% | +7.9% |
| Morgan Stanley | 16.49M | 5.06% | -8.2% |
| RTW Investments LP | 13.56M | 4.16% | -0.9% |
| FMR, LLC | 13.34M | 4.09% | -6.9% |
| Vanguard Capital Management LLC | 12.48M | 3.83% | +22.0% |
| State Street Corporation | 11.42M | 3.51% | +1.9% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of TSHA
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 9.14M | 2.80% |
| iShares Trust-iShares Russell 2000 ETF | 6.15M | 1.89% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 5.88M | 1.80% |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.17M | 1.28% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 3.04M | 0.93% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 2.62M | 0.80% |
| iShares Trust-iShares Russell 2000 Growth ETF | 2.26M | 0.69% |
| iShares Trust-iShares Biotechnology ETF | 1.99M | 0.61% |
| abrdn Life Sciences Investors | 1.50M | 0.46% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 1.31M | 0.40% |
Frequently asked questions
Who is the largest shareholder of Taysha Gene Therapies?
Avoro Capital Advisors LLC is the largest institutional shareholder of TSHA, owning 7.33% of shares outstanding (23.89M shares) as of its latest 13F filing.
What percentage of Taysha Gene Therapies is owned by institutions?
Institutions own about 94.1% of TSHA shares and 103.9% of the public float.
How much of Taysha Gene Therapies do insiders own?
Insiders, such as officers and directors, own about 9.45% of TSHA shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.